Conduit Pharmaceuticals Inc
NASDAQ:CDT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C
|
Conduit Pharmaceuticals Inc
NASDAQ:CDT
|
US |
|
B
|
Banco de Credito e Inversiones
SGO:BCI
|
CL |
|
Towngas Smart Energy Co Ltd
HKEX:1083
|
HK |
|
S
|
SCG Ceramics PCL
SET:COTTO
|
TH |
|
X
|
Xencor Inc
F:XE9
|
US |
|
H
|
Hangzhou Fortune Gas Cryogenic Group Co Ltd
SSE:603173
|
CN |
|
Writeup Co Ltd
TSE:6580
|
JP |
|
Hopson Development Holdings Ltd
HKEX:754
|
HK |
|
A
|
Arise AB
STO:ARISE
|
SE |
|
I
|
Indag Rubber Ltd
BSE:509162
|
IN |
|
Cognition Therapeutics Inc
NASDAQ:CGTX
|
US |
|
P
|
Prodigy PCL
SET:PDG
|
TH |
|
Payoneer Global Inc
NASDAQ:PAYO
|
US |
|
Anhui Zhongding Sealing Parts Co Ltd
SZSE:000887
|
CN |
|
T
|
Tokmanni Group Corp
LSE:0RG2
|
FI |
|
Nihon Jyoho Create Co Ltd
TSE:4054
|
JP |
Conduit Pharmaceuticals Inc
Conduit Pharmaceuticals Inc is a US-based company operating in industry. The company is headquartered in San Diego, California. The company went IPO on 2022-02-03. Conduit Pharmaceuticals, Inc. is a disease agnostic life science company. The firm is engaged in the development and commercialization of clinical assets to address the unmet medical needs of patients. The Company’s licensed clinical assets are focused on idiopathic male infertility and autoimmune diseases or immunodeficient conditions like uveitis, preterm labor, renal transplant rejection and Hashimoto’s Thyroiditis. The Company’s asset pipeline includes AZD1656 (a Glucokinase Activator), and AZD5904 (a Myeloperoxidase Inhibitor). AZD1656 is a glucokinase activator used in diabetes mellitus. The company is used as a treatment option for Hashimoto’s Thyroiditis (HT) and Graves’ disease, including investigating any negative side effects of the use of AZD1656 as compared with treatment options for Hashimoto’s Thyroiditis and Graves’ disease. AZD5904 includes a potent, irreversible inhibitor of human myeloperoxidase (MPO), that has the potential to treat Idiopathic Male Infertility (IMI).
Conduit Pharmaceuticals Inc is a US-based company operating in industry. The company is headquartered in San Diego, California. The company went IPO on 2022-02-03. Conduit Pharmaceuticals, Inc. is a disease agnostic life science company. The firm is engaged in the development and commercialization of clinical assets to address the unmet medical needs of patients. The Company’s licensed clinical assets are focused on idiopathic male infertility and autoimmune diseases or immunodeficient conditions like uveitis, preterm labor, renal transplant rejection and Hashimoto’s Thyroiditis. The Company’s asset pipeline includes AZD1656 (a Glucokinase Activator), and AZD5904 (a Myeloperoxidase Inhibitor). AZD1656 is a glucokinase activator used in diabetes mellitus. The company is used as a treatment option for Hashimoto’s Thyroiditis (HT) and Graves’ disease, including investigating any negative side effects of the use of AZD1656 as compared with treatment options for Hashimoto’s Thyroiditis and Graves’ disease. AZD5904 includes a potent, irreversible inhibitor of human myeloperoxidase (MPO), that has the potential to treat Idiopathic Male Infertility (IMI).
